WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has agreed to provide additional funding of $9.2 million to its existing contract with Enanta to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics known as Bicyclolides. NIAID is funding development of the Bicyclolides for use as medical countermeasures against multiple biodefense Category A and B bacteria. This brings total funding from NIAID to date to approximately $23.5 million. As part of a multi-year contract that was awarded in 2011, this funding could total approximately $42.7 million if all project milestones are met and NIAID exercises all its options to fund additional development under the contract.
Help employers find you! Check out all the jobs and post your resume.